85
Participants
Start Date
March 23, 2022
Primary Completion Date
December 20, 2023
Study Completion Date
March 31, 2027
Venetoclax
Venetoclax 400 mg po on days 1, 8, 15 and 22 of each cycle (28-day cycle)
Decitabine
Decitabine 0.2 mg/kg SQ (subcutaneous) on days 2, 9, 16, 23 (for aggressive disease will add decitabine on days 3, 10, 17, 24)
RECRUITING
Montefiore Medical Center, The Bronx
RECRUITING
White Plains Hospital, White Plains
RECRUITING
University of California Davis Health (UC Davis Health), Sacramento
The V Foundation for Cancer Research
OTHER
Montefiore Medical Center
OTHER